Keros Therapeutics/KROS

$68.85

1.99%
-
1D1W1MYTD1YMAX

About Keros Therapeutics

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need. Its protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes (MDS) and myelofibrosis. Its lead small molecule product candidate, KER-047, is being developed for the treatment of functional iron deficiency. Its third product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, and for the treatment of cardiovascular disorders. Its KER-050 is an engineered ligand trap comprised of a modified ligand-binding domain of the transforming growth factor-beta (TGF-B) receptor. It is designed to raise red blood cell and platelet production.

Ticker

KROS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jasbir Seehra

Employees

136

Headquarters

Lexington, United States

KROS Metrics

BasicAdvanced
$2.48B
Market cap
-
P/E ratio
-$5.19
EPS
1.28
Beta
-
Dividend rate

What the Analysts think about KROS

Analyst Ratings

Majority rating from 11 analysts.
Buy

Price Targets

Average projection from 9 analysts.
24.43% upside
High $105.00
Low $60.00
$68.85
Current price
$85.67
Average price target

KROS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-40,200% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$100K
∞%
Net income
$-40.2M
2.03%
Profit margin
-40,200%
-∞%

KROS Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 2.51%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$1.26
-$1.27
-$1.33
-$1.34
-
Expected
-$1.12
-$1.34
-$1.35
-$1.37
-$1.31
Surprise
12.21%
-5.12%
-1.31%
-2.51%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Keros Therapeutics stock

Buy or sell Keros Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing